A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: an intestinal anti-inflammatory response is suggested.

Matthew Bambling, Sophie C Edwards, Sean Hall, Luis Vitetta

Journal: Inflammopharmacology 2017;25(2):271-274

PMID: 28155119

Abstract

Approximately, one-third of those who develop major depression will have a poor response to treatment and over time can become treatment resistant. Intestinal dysbiosis has been implicated in depression with systemic inflammation and vagal and enteric nerve impairment. We report on a sequel pilot study (n = 12) with a combination probiotics/magnesium orotate formulation adjuvant administered with SSRIs for treatment resistant depression. At the end of an 8-week intervention mean changes for depression scores and quality of life in the group was clinically significantly improved (p < 0.001) with all but 4 participants experiencing a benefit. An intestinal anti-inflammatory response was suggested. At 16-weeks follow-up while still on SSRI medications, the group had relapsed after cessation of the test intervention.

Address: Faculty of Medicine, The University of Queensland, 288 Herston Road, Herston, Brisbane, QLD, 4006, Australia. [email protected].; Faculty of Medicine, The University of Queensland, 288 Herston Road, Herston, Brisbane, QLD, 4006, Australia.; Medlab Clinical Ltd., Sydney, Australia.; Medlab Clinical Ltd., Sydney, Australia. [email protected].; Sydney Medical School, The University of Sydney, Sydney, NSW, 2015, Australia. [email protected].

DOI: 10.1007/s10787-017-0311-x

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/28155119

MeSH Terms: Adult, Anti-Inflammatory Agents, Antidepressive Agents, Cohort Studies, Depressive Disorder, Treatment-Resistant, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Tract, Humans, Male, Middle Aged, Orotic Acid, Pilot Projects, Probiotics, Selective Serotonin Reuptake Inhibitors